Sugi Predict

Sugi Predict / Compounds / SCHEMBL867042

SCHEMBL867042

SCHEMBL867042

Oc1ncnn2cccc12

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 8/20 0.60
▸ PIK3CA P42336 1/20 0.47
▸ EGFR P00533 2/20 0.47
▸ KDR P35968 2/20 0.47
▸ PDE10A Q9Y233 1/20 0.41
▸ IRAK4 Q9NWZ3 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ JAK2 O60674 1/20 0.36
▸ AAK1 Q2M2I8 2/20 0.36
▸ GLA P06280 1/20 0.36
▸ NCOA1 Q15788 1/20 0.35
▸ NCOA3 Q9Y6Q9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17130415 0.77 MAP4K4 (0.62) MAP4K4PIK3CAEGFRKDRPDE10A
SCHEMBL25776743 0.75 MAP4K4 (0.60) MAP4K4PIK3CAEGFRKDRPDE10A
SCHEMBL864036 0.75 MAP4K4 (0.60) MAP4K4PIK3CAEGFRKDRPDE10A
SCHEMBL58274 0.75 MAP4K4 (1.00) MAP4K4PIK3CAEGFRKDRPDE10A
SCHEMBL4818798 0.75 MAP4K4 (0.60) MAP4K4PIK3CAEGFRKDRPDE10A
SCHEMBL14044627 0.75 MAP4K4 (0.60) MAP4K4PIK3CAEGFRKDRPDE10A
SCHEMBL12259691 0.75 MAP4K4 (0.55) MAP4K4PIK3CAEGFRKDRPDE10A
SCHEMBL9976122 0.75 MAP4K4 (0.59) MAP4K4PIK3CAEGFRKDRPDE10A
SCHEMBL14758192 0.75 MAP4K4 (0.55) MAP4K4PIK3CAEGFRKDRPDE10A
Hydrochloric Acid SCHEMBL15019896 0.73 MAP4K4 (0.96) MAP4K4PIK3CAEGFRKDRPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12522595-B2 Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2026-01-13 — — US disclosed
WO-2025080653-A1 PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUNDS ACTING AGAINST CANCERS, INFLAMMATORY DISEASES, AND FIBROTIC DISEASE VIA INTERACTION WITH RAS SUPERFAMILY PROTEINS SHY THERAPEUTICS, LLC (US) 2025-04-17 — — WO disclosed
EP-4504341-A1 COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE Shy Therapeutics LLC (US) 2025-02-12 — — EP disclosed
WO-2023196975-A1 COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE SHY THERAPEUTICS, LLC (US) 2023-10-12 — — WO disclosed
EP-3743430-B1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 — — EP disclosed
EP-3743430-B1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 — — EP disclosed
US-11618753-B2 Aminopyrrolotriazines as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2023-04-04 — — US disclosed
US-20220204539-A1 CD73 INHIBITORS BIOARDIS LLC 2022-06-30 — — US disclosed
US-20220204539-A1 CD73 INHIBITORS BIOARDIS LLC 2022-06-30 — — US disclosed
US-20220106305-A1 BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS BIOGEN MA INC. 2022-04-07 — — US disclosed
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. 2011-02-24 — — US disclosed
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. 2011-02-24 — — US disclosed
WO-2010014930-A2 THERAPEUTIC AGENTS BIOCRYST PHARMACEUTICALS, INC. (US) 2010-02-04 — — WO disclosed
WO-2009091939-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. (US) 2009-07-23 — — WO disclosed
US-7439246-B2 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-10-21 — — US disclosed
CN-101027305-A Fused heterocyclic kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2007-08-29 — — CN disclosed
US-7173031-B2 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-06 — — US disclosed
US-20060211695-A1 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-09-21 — — US disclosed
US-20060004006-A1 Pyrrolotriazine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-01-05 — — US disclosed
US-20050288290-A1 Fused heterocyclic kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288290-A1 Fused heterocyclic kinase inhibitors MAP3K20, MAP3K19, ABL1 MAP4K4 24/4885PIK3CA 119/4885EGFR 408/4885
US-20060004006-A1 Pyrrolotriazine kinase inhibitors MAP3K5, MAP3K15, MAP4K2 MAP4K4 28/4885PIK3CA 338/4885EGFR 1009/4885
US-20060211695-A1 Fused heterocyclic kinase inhibitors MAP3K20, MAP3K19, ABL1 MAP4K4 24/4885PIK3CA 119/4885EGFR 408/4885
US-20220204539-A1 CD73 INHIBITORS ENTPD5, ENTPD1, ENTPD2 MAP4K4 4593/4885PIK3CA 432/4885EGFR 1541/4885
US-20220106305-A1 BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS ENGASE, UGGT1, MGAT3 MAP4K4 4044/4885PIK3CA 3376/4885EGFR 1824/4885
US-11618753-B2 Aminopyrrolotriazines as kinase inhibitors RIPK1, RIPK2, RIPK4 MAP4K4 193/4885PIK3CA 1071/4885EGFR 3754/4885
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS IGF1R, IGFBP3, INSR MAP4K4 665/4885PIK3CA 872/4885EGFR 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.